CAMP4 Therapeutics (NASDAQ:CAMP) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• CAMP4 Therapeutics shares climbed above their 200-day moving average, reaching $5.18 before last trading at $4.90, compared with the $4.32 average.
• Analyst sentiment is mixed but leans positive: seven analysts rate the stock a Buy and two rate it a Sell, producing a “Moderate Buy” consensus and a $9.56 average price target.
• The company reported a substantial quarterly EPS miss, losing $0.58 per share versus the $0.24 expected, while revenue totaled $1.78 million; insiders have bought 36,031 shares over the past three months.

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.32 and traded as high as $5.18. CAMP4 Therapeutics shares last traded at $4.90, with a volume of 128,474 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CAMP. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, June 10th. Zacks Research lowered CAMP4 Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday, July 15th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.56.

CAMP4 Therapeutics Trading Down 2.0%

The firm has a market capitalization of $307.48 million, a price-to-earnings ratio of -2.11 and a beta of 0.22. The firm has a fifty day moving average price of $4.10 and a 200 day moving average price of $4.32.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, equities analysts predict that CAMP4 Therapeutics Corporation will post -0.66 EPS for the current fiscal year.

Insider Activity

In other CAMP4 Therapeutics news, Director Richard A. Young purchased 16,378 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the acquisition, the director directly owned 186,388 shares of the company's stock, valued at $307,540.20. This represents a 9.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 36,031 shares of company stock valued at $59,451 over the last three months. Insiders own 21.69% of the company's stock.

Institutional Investors Weigh In On CAMP4 Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC bought a new position in shares of CAMP4 Therapeutics in the second quarter worth about $36,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $61,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $78,000. Finally, OMERS ADMINISTRATION Corp bought a new position in CAMP4 Therapeutics in the 4th quarter worth approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source